Read More

Genmab, BioNTech Announced Data At ASCO, Showing Investigational Acasunlimab In Combination With Pembrolizumab Resulted In 12-month Overall Survival Rate of 69% In Patients With Previously Treated Metastatic Non-small Cell Lung Cancer

Genmab A/S (NASDAQ:GMAB) and BioNTech SE (NASDAQ:BNTX) todayannounced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also

BNTX

Read More

Gilead And Arcus Announced Etrumadenant Plus Zimberelimab, FOLFOX, And Bevacizumab Reduce Death Risk By 63% And Disease Progression by 73% vs Regorafenib In Phase 1b/2 Trial For Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. (NASDAQ:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced new data from Cohort B of ARC-9, a Phase 1b/2 study evaluating the safety and efficacy of etrumadenant, a dual A2a/b adenosine

GILD

Read More

ALX Oncology Reported Phase 1 ASPEN-07 Data In in Patients with Advanced Bladder Cancer AT ASCO 2024; Initial Activity Showed Tumor Reduction In The Majority Of Evaluable Patients

ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (NASDAQ: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented dataALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (NASDAQ:

ALXO

Read More

Frank McCourt Organizes Bid to Acquire TikTok in U.S.

Frank McCourt, Founder of Project Liberty and Executive Chairman of McCourt Global, today announced that Project Liberty is organizing a bid to acquire the popular social media platform TikTok in the U.S., with the goal of placing people and data empowerment at the center of the platform's design and purpose.

FXI